BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 27662291)

  • 1. Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects.
    Araque Caballero MÁ; Klöppel S; Dichgans M; Ewers M;
    J Alzheimers Dis; 2017; 55(1):343-358. PubMed ID: 27662291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping 3-year changes in gray matter and metabolism in Aβ-positive nondemented subjects.
    Araque Caballero MÁ; Brendel M; Delker A; Ren J; Rominger A; Bartenstein P; Dichgans M; Weiner MW; Ewers M;
    Neurobiol Aging; 2015 Nov; 36(11):2913-2924. PubMed ID: 26476234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex differences in the association between AD biomarkers and cognitive decline.
    Koran MEI; Wagener M; Hohman TJ;
    Brain Imaging Behav; 2017 Feb; 11(1):205-213. PubMed ID: 26843008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease.
    Dicks E; Vermunt L; van der Flier WM; Visser PJ; Barkhof F; Scheltens P; Tijms BM;
    Neuroimage Clin; 2019; 22():101786. PubMed ID: 30921610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations Between the Subjective Cognitive Decline-Questionnaire's Scores, Gray Matter Volume, and Amyloid-β Levels.
    Valech N; Sánchez-Benavides G; Tort-Merino A; Coll-Padrós N; Olives J; León M; Falcon C; Molinuevo JL; Rami L
    J Alzheimers Dis; 2019; 72(4):1287-1302. PubMed ID: 31707366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects.
    Ewers M; Insel P; Jagust WJ; Shaw L; Trojanowski JQ; Aisen P; Petersen RC; Schuff N; Weiner MW;
    Cereb Cortex; 2012 Sep; 22(9):1993-2004. PubMed ID: 22038908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease.
    Hohman TJ; Bell SP; Jefferson AL;
    JAMA Neurol; 2015 May; 72(5):520-9. PubMed ID: 25751166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's disease.
    Mecca AP; Barcelos NM; Wang S; Brück A; Nabulsi N; Planeta-Wilson B; Nadelmann J; Benincasa AL; Ropchan J; Huang Y; Gelernter J; Van Ness PH; Carson RE; van Dyck CH
    Neurobiol Aging; 2018 Jan; 61():207-214. PubMed ID: 29111487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.
    Doré V; Villemagne VL; Bourgeat P; Fripp J; Acosta O; Chetélat G; Zhou L; Martins R; Ellis KA; Masters CL; Ames D; Salvado O; Rowe CC
    JAMA Neurol; 2013 Jul; 70(7):903-11. PubMed ID: 23712469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment.
    Ten Kate M; Barkhof F; Visser PJ; Teunissen CE; Scheltens P; van der Flier WM; Tijms BM
    Alzheimers Res Ther; 2017 Sep; 9(1):73. PubMed ID: 28899429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease.
    Kljajevic V; Grothe MJ; Ewers M; Teipel S;
    Neurobiol Aging; 2014 Sep; 35(9):1973-81. PubMed ID: 24811241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife.
    Racine AM; Koscik RL; Berman SE; Nicholas CR; Clark LR; Okonkwo OC; Rowley HA; Asthana S; Bendlin BB; Blennow K; Zetterberg H; Gleason CE; Carlsson CM; Johnson SC
    Brain; 2016 Aug; 139(Pt 8):2261-74. PubMed ID: 27324877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in Mild Cognitive Impairment.
    Kandel BM; Avants BB; Gee JC; Arnold SE; Wolk DA;
    J Alzheimers Dis; 2015; 46(4):901-12. PubMed ID: 25881908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional patterns of gray matter volume, hypometabolism, and beta-amyloid in groups at risk of Alzheimer's disease.
    Wirth M; Bejanin A; La Joie R; Arenaza-Urquijo EM; Gonneaud J; Landeau B; Perrotin A; Mézenge F; de La Sayette V; Desgranges B; Chételat G
    Neurobiol Aging; 2018 Mar; 63():140-151. PubMed ID: 29203090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects.
    Ewers M; Brendel M; Rizk-Jackson A; Rominger A; Bartenstein P; Schuff N; Weiner MW;
    Neuroimage Clin; 2014; 4():45-52. PubMed ID: 24286024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease.
    Lim YY; Ellis KA; Harrington K; Kamer A; Pietrzak RH; Bush AI; Darby D; Martins RN; Masters CL; Rowe CC; Savage G; Szoeke C; Villemagne VL; Ames D; Maruff P;
    Neuropsychology; 2013 May; 27(3):322-332. PubMed ID: 23688214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-AV45 PET and MRI Reveal the Influencing Factors of Alzheimer's Disease Biomarkers in Subjective Cognitive Decline Population.
    Zhao Z; Wang J; Wang Y; Liu X; He K; Guo Q; Xie F; Huang Q; Li Z
    J Alzheimers Dis; 2023; 93(2):585-594. PubMed ID: 37066915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.